La Securities and Exchange Commission, l'Autorité de marché des États-Unis a publié un communiqué de presse dans lequel elle accuse le groupe pharmaceutique Eli Lilly and Company pour violation des règles FCPA.
Eli Lilly and Company aurait versé des pots-de-vin à travers ses filiales à des agents publics étrangers afin de gagner des contrats de plusieurs millions de dollars en Russie, au Brésil, en Chine et en Pologne.
Le groupe pharmaceutique a accepté de payer l'amende de 29 millions de dollars afin de régler les accusations de la SEC.
The SEC alleges that the Indianapolis-based pharmaceutical company’s subsidiary in Russia used offshore “marketing agreements” to pay millions of dollars to third parties chosen by government customers or distributors, despite knowing little or nothing about the third parties beyond their offshore address and bank account information. These offshore entities rarely provided any services and in some instances were used to funnel money to government officials in order to obtain business for the subsidiary. Transactions with offshore or government-affiliated entities did not receive specialized or closer review for possible FCPA violations. Paperwork was accepted at face value and little was done to assess whether the terms or circumstances surrounding a transaction suggested the possibility of foreign bribery.
The SEC alleges that when the company did become aware of possible FCPA violations in Russia, Lilly did not curtail the subsidiary’s use of the marketing agreements for more than five years. Lilly subsidiaries in Brazil, China, and Poland also made improper payments to government officials or third-party entities associated with government officials. Lilly agreed to pay more than $29 million to settle the SEC’s charges.
Télécharger le document